PERRIGO Co plc
PRGO evidence brief
What we can confirm
- BioSniper Score:
- 7.6 / 10
- Market Cap:
- $2.02B
- Lead Asset:
- minoxidil (Approved)
What it means
What to watch
Prepared research question
What matters most for PRGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRGO
Perrigo Co plc (PRGO) is a global consumer self-care and pharmaceutical company that develops, manufactures, and markets over-the-counter (OTC) and generic prescription drugs, with a focus on store-brand products.
Key risk: Declining net sales guidance
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 27, 2026.
Tracking 3 pipeline candidates · 1 clinical trial · 5 FDA decisions for PERRIGO Co plc.
Perrigo Co plc (PRGO) is a global consumer self-care and pharmaceutical company that develops, manufactures, and markets over-the-counter (OTC) and generic prescription drugs, with a focus on store-brand products.
- Total revenue of $1,022.8M and net income of $74.5M as of 2026-06-27 [sec].
- Shareholders' equity of $2,515.8M as of 2026-06-27 [sec].
- Q2 2026 earnings and revenue surpassed estimates by +61.29% and +1.89%, respectively [news · published 2026-08-05].
- FY2026 adjusted EPS guidance affirmed at $2.25-$2.55 and sales guidance at $4.019B-$4.189B [news · published 2026-05-06].
- Pipeline includes an approved minoxidil topical aerosol foam candidate [pipeline].
What works
- Q2 2026 earnings and revenue beat consensus estimates, with adjusted EPS outperforming by +61.29% [news · published 2026-08-05].
- Strong Infant Formula sales contributed to the Q2 earnings beat [news · published 2026-08-08].
- Management noted 'meaningful progress' in 2025 and market share gains in core business [news · published 2026-02-28][news · published 2026-03-16].
What to weigh
- Net sales guidance for FY2026 projects a decline of 5.5% to 1.5% [news · published 2026-08-08].
- Share price has declined 61.9% over the past three years [news · published 2026-08-09].
- Challenges persist in infant formula and a softer consumer health market [news · published 2026-02-28].
From the filings
Quoted directly from source documents.
Q2 2026 earnings and revenue beat estimates
“Perrigo (PRGO) delivered earnings and revenue surprises of +61.29% and +1.89%, respectively, for the quarter ended June 2026.”
News · August 5, 2026
FY2026 guidance affirmed
“Perrigo (NYSE:PRGO) affirms FY2026 Adj EPS guidance from $2.25-$2.55 to $2.25-$2.55 vs $2.11 analyst estimate. Affirms FY2026 sales outlook from $4.019 billion-$4.189 billion to $4.019 billion-$4.189 billion vs $4.114”
News · May 6, 2026
Share price decline over three years
“The share price has declined 61.9% over the past 3 years”
News · August 9, 2026
Approved minoxidil pipeline candidate
“Pipeline Candidate: minoxidil Generic Name: MINOXIDIL Phase: Approved Delivery Vector: TOPICAL AEROSOL, FOAM”
Catalyst timeline
- 2026-07-13 · Patent_Expiry: NDA017031 — Patent expiry on NDA017031 may open opportunities for generic competition or affect Perrigo's market position.
Risks & what to watch (3)›
Key risks
- Declining net sales guidance — FY2026 net sales guidance projects a decline of 5.5% to 1.5% [news · published 2026-08-08].
- Share price decline — Stock has fallen 61.9% over three years, indicating prolonged underperformance [news · published 2026-08-09].
- Infant formula challenges — Continued challenges in infant formula and softer consumer health market noted [news · published 2026-02-28].
What to watch
- Q3 2026 earnings and revenue performance to see if Q2 beat continues [news · published 2026-08-05].
- Infant formula sales trajectory and market share developments [news · published 2026-08-08].
- FY2026 full-year net sales outcome relative to the 5.5%-1.5% decline guidance [news · published 2026-08-08].
- Patent expiry on NDA017031 on 2026-07-13, which may affect competitive landscape [catalyst].
Sources: Catalysts · News · Pipeline · Generated October 5, 2026 · How we verify sources →
Run PERRIGO Co plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PERRIGO Co plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.02 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 15.6%
- Days to cover
- 3.8
- Shares short
- 13,922,505
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRGO short interestGovernance
Frequently asked questions
What is the AI investment thesis for PERRIGO Co plc?
Perrigo Co plc (PRGO) is a global consumer self-care and pharmaceutical company that develops, manufactures, and markets over-the-counter (OTC) and generic prescription drugs, with a focus on store-brand products.
What is PERRIGO Co plc's lead drug candidate?
PERRIGO Co plc's most advanced tracked candidate is minoxidil (Approved).
Who is the CEO of PERRIGO Co plc?
Mr. Albert Ange Manzone is the chief executive officer of PERRIGO Co plc (PRGO).
Where is PERRIGO Co plc headquartered?
PERRIGO Co plc (PRGO) is headquartered in Dublin, Ireland.
What therapeutic areas does PERRIGO Co plc focus on?
PERRIGO Co plc develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.